Gamma-aminobutyric acid type A receptor subunit alpha-2 (GABRA2)

The alpha-2 subunit-containing GABA-A receptor is a pentameric ligand-gated ion channel that mediates fast inhibitory neurotransmission in the central nervous system (nih.gov, 1.3.2). It is primarily composed of two alpha-2 subunits, two beta subunits, and one gamma-2 subunit, forming a chloride-selective pore (wikipedia.org, 1.2.1). This receptor subtype is highly expressed in the hippocampus and limbic system, where it plays a critical role in regulating emotional states and reward processing (nih.gov, 1.3.2). Pharmacologically, it is a key target for anxiolytic and analgesic drugs because it mediates the anti-anxiety and antihyperalgesic effects of benzodiazepines (nih.gov, 1.3.1). Unlike the alpha-1 subtype, which is associated with sedation and cognitive impairment, the alpha-2 subtype is targeted to provide therapeutic benefits without these side effects (mdpi.com, 1.1.1). Genetic variations in the GABRA2 gene have been strongly linked to an increased risk of alcohol dependence and other substance use disorders (nih.gov, 1.2.4). Mutations in the alpha-2 subunit are also associated with severe neurodevelopmental conditions such as Developmental and Epileptic Encephalopathy 78 (DEE78) (rupahealth.com, 1.2.3). Current drug development efforts focus on selective positive allosteric modulators, such as darigabat, to treat conditions like treatment-resistant epilepsy and chronic pain (nih.gov, 1.4.1).

Other names

GABRA2GABA(A) receptor subunit alpha-2Alpha-2 subunit-containing GABA-A receptorGABA(A) receptor alpha-2α2-GABA_A receptor

Positive allosteric modulation (PAM) at the benzodiazepine binding site located at the interface of the alpha and gamma subunits (nih.gov, 1.4.2).